

1 **Polymicrobial *Candida* biofilms: friends and foe in the oral cavity**

2

3 Lindsay E. O'Donnell, Emma Millhouse, Leighann Sherry, Ryan Kean, Jennifer
4 Malcolm, Christopher J. Nile and *Gordon Ramage

5

6 *Infection and Immunity Research Group, Glasgow Dental School, School of
7 Medicine, College of Medical, Veterinary and Life Sciences, University of
8 Glasgow, Glasgow, UK.

9

10 KEYWORDS:

11

12 RUNNING TITLE: Polymicrobial candidal biofilms

13

14 *Corresponding Author: Gordon Ramage, Infection and Immunity Research
15 Group, Glasgow Dental School, School of Medicine, College of Medical,
16 Veterinary and Life Sciences, University of Glasgow, 378 Sauchiehall Street,
17 Glasgow, G2 3JZ, UK. Phone: +44(0)141 211 9752. email:
18 gordon.ramage@glasgow.ac.uk

19

20

21

22

23

24

25

26

27

28

29

30

31

32

33

34

35 **ABSTRACT**

36 The role of polymicrobial biofilm infections in medicine is becoming more
37 apparent. Increasing numbers of microbiome studies and deep sequencing
38 has enabled us to develop a greater understanding of how positive and
39 negative microbial interactions influence disease outcomes. An environment
40 where this is particularly pertinent is within the oral cavity, a rich and diverse
41 ecosystem inhabited by both bacteria and yeasts, which collectively occupy
42 and coexist within various niches as biofilm communities. Studies within this
43 environment have however tended to be subject to extensive independent
44 investigation, in the context of either polymicrobial bacterial communities or
45 yeast biofilms, but rarely both together. It is clear however that they are not
46 mutually exclusive. Therefore, this review aims to explore the influence of
47 candidal populations on the composition of these complex aggregates and
48 biofilm communities, to investigate their mechanistic interactions to understand
49 how these impact clinical outcomes, and determine whether we can translate
50 how this knowledge can be used to improve patient management.

51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68

69 **Introduction**

70 *Candida* biofilms, in particular *C. albicans*, are an important healthcare issue
71 due to ineffective clinical management strategies. Over the past 20 years we
72 have learned a great deal about their clinical importance, including the
73 mechanisms used by members of the genus to form biofilms and resist the
74 challenge of host and antimicrobial molecules (Nett, 2014, Ramage *et al.*,
75 2014). However, as our levels of knowledge have increased, in part through
76 the development of more sophisticated technologies, there has been a
77 growing awareness that *Candida* rarely exist within a mono-species
78 environment, and that heterogeneous biofilm populations consisting of
79 aggregates of other fungi and bacteria (Gram-positive and Gram-negative) are
80 in fact a highly prevalent and clinically important entity (Figure 1).

81

82 One location within the body where *Candida* species are readily isolated is
83 within the oral cavity. Traditionally oral microbiologists have invested
84 significant time and effort unravelling the importance of specific bacterial-
85 bacterial interactions, while investigations of polymicrobial interactions have
86 not received the same level of attention. This has led to a disparity of
87 fundamental knowledge on the significance of candidal-bacterial interactions
88 within the oral environment. The clinical implications of these polymicrobial
89 biofilm interactions, primarily relates to recalcitrance to antimicrobial treatment
90 strategies. Moreover, there is growing evidence from the literature that
91 polymicrobial interactions may synergise the pathogenic potential of one or
92 other microorganism (Stacy *et al.*, 2014). This only serves to highlight the
93 importance of a dual approach to microbial analysis, where mycological and
94 bacteriological analysis can have an equal contribution through
95 interdisciplinary collaboration (Holmes *et al.*, 1995). This review aims to
96 critically evaluate the available evidence as a means of appraising the clinical
97 importance of *Candida* biofilms in polymicrobial environments, using key oral
98 diseases and groups of microorganisms to illustrate these points.

99

100 **Polymicrobial candidal interactions in the oral cavity**

101 Oral candidosis is one of the most well-defined fungal biofilm infections of both
102 soft and hard tissue and is characterised by complex biofilms which interact

103 with bacteria and the host (Dongari-Bagtzoglou *et al.*, 2009, Rautemaa &
104 Ramage, 2011). The oral cavity provides a key portal of entry within the
105 human host, and is home to a rich and diverse microbial flora. Despite being
106 bathed in saliva, an important innate defence mechanisms containing
107 numerous antimicrobial molecules, the oral cavity is a favourable habitat for
108 both prokaryotes and eukaryotes. Within this, it is suggested that up to 10^8
109 microbes per millilitre of saliva are present (Guo & Shi, 2013). The oral cavity,
110 therefore, acts as an important incubator for a complex 'microbial soup', in
111 which yeasts such as *Candida* interact with one-another and with a plethora of
112 cultivatable and non-cultivatable bacterial species, primarily within biofilm
113 communities. Advances in genome sequencing are only now beginning to
114 shed light on the importance of *Candida* within these complex communities
115 (Nobbs & Jenkinson, 2015). Microbiome analysis of the saliva from elderly
116 Dutch patients showed that an increased candidal load was associated with a
117 dysbiotic bacterial flora that favoured the co-existence with oral streptococci to
118 the exclusion of pathogenic anaerobic species (Kraneveld *et al.*, 2012).
119 *Candida* species have been isolated from a range of oral environments
120 involving both soft and hard tissue of biological and non-biological origin,
121 illustrating the adaptability of candidal yeasts (Figure 2). The sites from which
122 *C. albicans* has been isolated include periodontal pockets, root canals,
123 orthodontic appliances, enamel, dentures and mucosal surfaces (Ramage *et al.*,
124 2004, de Carvalho *et al.*, 2006, Arslan *et al.*, 2008, Dongari-Bagtzoglou *et al.*,
125 2009, Sardi *et al.*, 2010, Freitas *et al.*, 2014). In order for candidal biofilms
126 to flourish in these environments, moisture, nutrients, hyphal growth and the
127 presence of commensal bacteria are all required which influence *C. albicans*
128 architecture and virulence (Bertolini *et al.*, 2015).

129

130 *Caries*

131 Dental caries is one of the most common diseases worldwide, impacting 2.43
132 billion (36% of the global population) (Vos *et al.*, 2012). Largely influenced by
133 diet caries has a multifactorial aetiology involving behavioural, environmental
134 and immunological factors. Microbial dental plaque biofilms adherent to tooth
135 surfaces, play a key role in the development of dental caries, through
136 carbohydrate metabolism (predominantly sucrose) leading to production of

137 large quantities of lactic acid, and ultimately the dissolution of tooth surfaces.
138 Typically, caries has been associated primarily with *Streptococcus mutans* and
139 *Lactobacillus* species (Loesche, 1986, Badet & Thebaud, 2008), although
140 more recently, oral microbiome studies have highlighted the polymicrobial
141 aetiology of carious lesions (Belda-Ferre *et al.*, 2012, Simon-Soro *et al.*, 2014).
142 Historically, candidal yeasts have been isolated in patients with caries (Krasse,
143 1954, Koo & Bowen, 2014), though the evidence for their direct role has yet
144 been shown directly. There is now growing evidence that *C. albicans* actively
145 participates in cariogenic biofilms, through synergistic interaction with *S.*
146 *mutans* (Metwalli *et al.*, 2013, Koo & Bowen, 2014). Evidence of enhanced
147 exopolymeric matrix production, facilitated by the increased surface area
148 associated with hyphal networks, supports mixed biofilm growth of dense
149 communities cemented to tooth enamel. Based on this and other studies, the
150 interaction between candidal yeasts and streptococci is an important area
151 requiring further extensive investigation.

152

153 *Periodontal disease*

154 Periodontal disease (PD) is a complex disease orchestrated by host-pathogen
155 interactions. It affects almost 50% of the US population under 30 years old,
156 and by the time they reach 65 years of age approximately 70% are affected
157 (Eke *et al.*, 2012). In its mild and reversible form (gingivitis) the gingival tissues
158 are characterised by swelling, an inflamed gum line and bleeding, whereas in
159 its severe and irreversible form (periodontitis) there is destruction of the
160 supporting periodontal ligaments and progressive bone resorption. While
161 dysregulated inflammatory responses are pivotal with respect to periodontitis,
162 the initial catalytic stimuli common to both forms of the disease comes from
163 complex microbial biofilms. These initially establish themselves above the gum
164 line (supra-gingival plaque), alter the microenvironment and drive a lower
165 redox and pH, thus enabling capnophiles and anaerobes to colonise and
166 produce sub-gingival plaque biofilms. The microbiology of supra- and sub-
167 gingival plaque is extremely well characterised, with the influence of defined
168 groupings of commensal and pathogenic species accurately mapped to clinical
169 outcomes (Ximenez-Fyvie *et al.*, 2000, Shi *et al.*, 2015). With this historical
170 focus on defined bacterial groupings defined by Socransky's traffic light

171 analogy (Socransky *et al.*, 1998), there has been minimal interest with respect
172 to the influence of candidal species (Holmstrup, 1999). This is surprising given
173 that *Candida* species have also been isolated from subgingival mixed biofilm
174 consortia in patients with severe chronic periodontitis, where quantitatively
175 high levels of *C. albicans* were shown to correlate with moderate and severe
176 chronic periodontitis (Canabarro *et al.*, 2012). There is, however, a lack of
177 direct evidence for causality, although in diabetes patients the relationship
178 between subgingival candidal colonisation and periodontitis is more apparent
179 (Sardi *et al.*, 2012, Hammad *et al.*, 2013). This relationship maybe a
180 consequence of metabolic requirements, with elevated blood sugar levels
181 supporting the growth of *Candida* species. Further evidence for *Candida*'s
182 involvement follows the use of oral contraceptives (OC), by which several
183 studies have found an increased prevalence of *Candida spp.* carriage, as well
184 as higher incidences of oral and vaginal candidiasis amongst OC users
185 (Spinillo *et al.*, 1995, Kazi *et al.*, 2012, Zakout *et al.*, 2012). Furthermore, the
186 prevalence of severe periodontitis is higher amongst OC users, suggesting
187 that the hormones lead to the development of a dysbiotic biofilm, enabling
188 *Candida* yeast to colonise (Brusca *et al.*, 2010). Irrespective of why *Candida*
189 spp. are present in this environment, we do know that the subgingival
190 environment represents a highly diverse microbial ecosystem comprised of a
191 variety of commensals and pathogens, ranging from benign streptococcal
192 species to virulent *Porphyromonas gingivalis* (Socransky & Haffajee, 2005,
193 Haffajee & Socransky, 2006). Here, competition for nutrients, gases and
194 space, dictate biofilm structure, and it is likely that the larger *Candida* cells play
195 a significant physical and chemical role.

196

197 *Endodontic infection*

198 Endodontitis can result from direct tooth trauma, carious lesions on the
199 enamel surface, or from periodontal infection progressing to the root apex. It
200 is characterised by an infection of the pulp within the dental root canal system
201 and is the major aetiologic agent of apical periodontitis. The American
202 Association of Endodontists estimate that over 15 million root canal
203 treatments are performed annually in the US, and these are primarily of an
204 infectious origin. Endodontic infections are typically of biofilm aetiology and

205 are associated with key oral bacterial pathogens from up to 100 different
206 bacterial genera (Siqueira & Rocas, 2009), by and large from 4 key phyla
207 (*Firmicutes*, *Bacteroidetes*, *Actinobacteria*, and *Proteobacteria*), although
208 *Enterococcus faecalis* is considered the primary aetiological agent.
209 Nonetheless, due consideration should be made to the method employed
210 (culture versus non-culture) when assembling the snapshot of the dominant
211 microbiota, as this heavily biases our perception of which species are
212 important. In fact, this is a pertinent point to all oral diseases. Endodontic
213 biofilms tend to reflect their origin, i.e. those from cariogenic lesion on occlusal
214 surfaces may be more similar to supra-gingival plaque whereas those in
215 periapical infection may reflect a predominantly anaerobic environment. There
216 is increasing evidence for the involvement of *Candida* species in endodontic
217 infections (Siqueira & Sen, 2004). Its' role as a dentophilic pathogen are
218 highlighted through *in vitro* studies of dentine, where penetration of dentine
219 tubules with *C. albicans* was demonstrated (Sen *et al.*, 1997). Subsequent
220 studies have confirmed the presence of *C. albicans* from clinical root canal
221 specimens (Baumgartner *et al.*, 2000), with subsequent studies showing an
222 association between *C. albicans* and *E. faecalis* (Peciuliene *et al.*, 2001). In
223 spite of this evidence of polymicrobiality there are no studies describing the
224 candidal-bacterial interactions in the root canal environment.

225

226 *Denture stomatitis*

227 Edentulousness is an irreversible clinical condition that can be described as
228 an ultimate marker of oral disease burden and is often associated with
229 socioeconomic factors (Jeganathan & Lin, 1992, Cunha-Cruz *et al.*, 2007).
230 Denture stomatitis (DS) refers to inflammation of the oral mucosa and
231 pathological changes associated with denture surfaces adjacent to tissue
232 (Jeganathan & Lin, 1992). Approximately two thirds of individuals who wear
233 removable complete dentures suffer from DS, though most individuals are
234 asymptomatic (Gendreau & Loewy, 2011). With 15 million dentures wearers in
235 the UK this is not an inconsequential disease (Coulthwaite & Verran, 2007).
236 Many factors influence its onset and severity, including salivary flow and
237 denture cleanliness amongst others (Oksala, 1990, Soysa *et al.*, 2004, Soysa
238 & Ellepola, 2005, Soysa *et al.*, 2006), although microbial factors remain one of

239 the most important. Dentures support the growth of microbial biofilms (denture
240 plaque) within tiny cracks and fissures. These polymicrobial biofilm
241 communities dominate the denture surface, with up to 10^{11} microbes per
242 milligram of denture plaque (Nikawa *et al.*, 1998), which take advantage of the
243 varied topography associated with denture acrylics and resins (Ramage *et al.*,
244 2004). Some of the bacterial species isolated include periodontal pathogens
245 such as *Fusobacterium nucleatum*, *Aggregatibacter actinomycetemcomitans*
246 and *Porphyromonas gingivalis* (Sachdeo *et al.*, 2008, Yasui *et al.*, 2012),
247 although caries-associated species such as *Streptococcus* and *Lactobacillus*
248 species predominate (Teles *et al.*, 2012), possibly through their ability to
249 coaggregate with *C. albicans* hyphae (Bilhan *et al.*, 2009, Ribeiro *et al.*, 2012).
250 Here they form biofilms analogous to that of the enamel surface through
251 pioneer species, followed by coaggregation and maturation of complex
252 polymicrobial biofilms (Figure 4).

253

254 Unlike the oral diseases described above, DS is generally considered to be of
255 yeast aetiology, with the literature disproportionately focussed on *Candida*
256 spp. (Coleman *et al.*, 1997, Bagg *et al.*, 2003, Redding *et al.*, 2004, Li *et al.*,
257 2007). *C. albicans* is the most frequently isolated yeast from the denture, but
258 *C. glabrata*, *C. dubliniensis*, *C. tropicalis*, *C. krusei* and a range of other
259 *Candida* species have been frequently isolated (Coco *et al.*, 2008, Williams *et*
260 *al.*, 2011). *C. albicans* accounts for the majority of the inflammatory pathology
261 observed clinically (Salerno *et al.*, 2011). It exists as a commensal in the oral
262 cavity of 25-50% of the healthy population, and can become pathogenic under
263 optimal conditions, such as when the immune response is compromised
264 (Dagistan *et al.*, 2009). This is not surprising given its dimorphic capabilities,
265 i.e. the ability to form hyphae and yeast interchangeably, a requisite of biofilm
266 formation (Ramage *et al.*, 2002). The hyphal form has been more commonly
267 isolated in DS sufferers and is assumed to be the more invasive form of the
268 organism, with an enhanced ability to adhere to and colonise the prosthesis
269 surface (Gendreau & Loewy, 2011, Verran *et al.*, 2014). Collectively, these
270 polymicrobial biofilms actively release proteolytic and lipolytic enzymes that
271 induce inflammation of the palatal surface (Marcos-Arias *et al.*, 2011, Ramage
272 *et al.*, 2012), ultimately leading to DS. The scanning electron micrograph

273 (SEM) in Figure 3 illustrates *C. albicans* interacting with bacteria on the
274 surface of denture acrylic, with the associated confocal micrograph, showing
275 bacteria coaggregating with *C. albicans* hyphae.

276

277 *Angular cheilitis*

278 Angular cheilitis is an inflammation of one, or more commonly both, corners of
279 the mouth. It is a disease of multifactorial aetiology that includes anatomical
280 issues, dry mouth, immunosuppression, and the wearing of poor fitting
281 dentures, amongst many others. Although not particularly common *per se*, this
282 disease is of interest as it is often associated with the co-isolation of *Candida*
283 species with *Staphylococcus aureus*, microorganisms not unaccustomed to
284 one another within the human host (Tawara *et al.*, 1996, Adam *et al.*, 2002,
285 Baena-Monroy *et al.*, 2005). Both species are leading pathogens in blood
286 borne and systemic infections, a major cause of morbidity and mortality in
287 hospitalized patients. These species are of significant interest because of the
288 escalating development of antimicrobial resistance and their increasing
289 involvement in chronic and systemic polymicrobial biofilm infections (Perlroth
290 *et al.*, 2007), and have been shown to co-aggregate together and exist within a
291 dynamic and interactive state (Peters *et al.*, 2012, Peters *et al.*, 2012) (Shirliff
292 *et al.*, 2009). The relationship between these two has been described as
293 mutualistic, synergistic and antagonistic, yet most of the evidence indicates
294 synergy, as the majority of their interactions are associated with enhanced
295 pathogenicity and disease severity (Peters & Noverr, 2013, Schlecht *et al.*,
296 2015).

297

298 *Oropharyngeal and respiratory infection*

299 As described, *Candida* is one of the main colonisers of the oral cavity and
300 plays an important role in many oral diseases. However, there is thought to be
301 a potential link between oral and pulmonary colonisation of *Candida*, which
302 could contribute towards respiratory infection. Studies have identified
303 respiratory pathogens colonising the oral cavity, as well as oral pathogens
304 colonising the lungs (El-Solh, 2011, Bansal *et al.*, 2013, Vadiraj *et al.*, 2013,
305 Przybylowska *et al.*, 2015). Amongst these, *Candida* has been found to be one
306 of the most predominant pathogens in the lungs, particularly in those suffering

307 from lung cancer and chronic pulmonary disease (Biswas et al., 2010,
308 Laroumagne et al., 2011, Laroumagne et al., 2013). Aspiration of oral material
309 into the lungs is thought to be the primary entry route of oral pathogens.
310 Therefore, given that the oral carriage rate of *Candida* is approximately 50%
311 (Darwazeh et al., 2010), and that roughly 45% of healthy individuals aspirate
312 oropharyngeal contents into their lungs whilst sleeping, this puts a high
313 number at risk of pulmonary colonisation by *Candida* (Gleeson et al., 1997).
314 Yet, despite the potential to cause infection, *Candida* colonisation of the lungs
315 is not necessarily detrimental, particularly when *P. aeruginosa* is also isolated
316 (Ader et al., 2011). *P. aeruginosa* is frequently related with ventilator
317 associated pneumonia and cystic fibrosis, with *C. albicans* often co-isolated.
318 Many studies have investigated their interactions, yet have produced
319 conflicting results with some identifying a synergistic relationship (Roux et al.,
320 2009); however the vast majority provide stronger evidence for an antagonistic
321 relationship (Morales et al., 2010, Bandara et al., 2013). *P. aeruginosa* gains
322 the upper hand the majority of the time by preventing biofilm formation via
323 killing of *C. albicans* hyphal filaments (Hogan & Kolter, 2002, Hogan et al.,
324 2004). Nonetheless, recently it has been shown in a murine model that lung
325 injury caused by *P. aeruginosa* infection is alleviated if preceded by a short
326 term *C. albicans* colonisation (Ader et al., 2011). This was due to *C. albicans*
327 activation of innate lymphoid cells, which produced IL-22, providing protection
328 against *P. aeruginosa* induced injury (Mear et al., 2014).

329

330 *Candida* polymicrobial biofilm formation is the predominant problem
331 associated with voice box prosthesis (VP) (Talpaert et al., 2015). Silicone is
332 the most commonly used material used for VP, however, silicone is a
333 favourable material for microbial attachment and can very quickly become
334 colonised (Busscher et al., 1997). Biofilm formation can lead to valve
335 malfunctioning, causing seepage of oesophageal contents into the trachea,
336 which could potentially cause aspiration pneumonia (van Weissenbruch et al.,
337 1997^a, van Weissenbruch et al., 1997^b). *C. albicans* is the most common
338 yeast associated with VP colonisation, though *C. glabrata* and *C. tropicalis* are
339 also frequently isolated (Bauters et al., 2002). *Streptococcus* spp and
340 *Lactobacillus* spp are the predominant bacterial species isolated (Neu et al.,

341 1994), however the majority of mature biofilms had *Candida* and lactobacilli as
342 their primary components (Buijssen et al., 2007). The success of polymicrobial
343 biofilms forming on VP is likely due to the location, which is difficult for host
344 immune defences to access. For the most part, it is very unusual to find a
345 biofilm from a VP that is not comprised of both fungal and bacterial
346 components. Before *Candida* can colonise the VP, there is strong evidence
347 that bacteria must be adhered first, thus such fungal-bacteria interactions are
348 critical for biofilm formation (Millsap et al., 2001). The more intricate details
349 involved in these interactions requires further investigation, however what is
350 clear is that disease resulting from microbial colonisation of a VP is very much
351 polymicrobial in nature.

352

353 **Mechanisms of polymicrobial biofilm interaction**

354 *Staphylococcal interactions*

355 The interaction between *C. albicans* and *S. aureus* has been associated with
356 enhanced pathogenic behaviour, disease severity and morbidity (Nair et al.,
357 2014). They form mixed polymicrobial biofilms in which *S. aureus* cells are
358 found attached to *C. albicans* hyphal filaments (Peters et al., 2010, Yi Jey Lin,
359 2013) (Figure 5). Their co-localisation within biofilms is still unclear, as some
360 describe them interspersed throughout the biofilm three-dimensional structure
361 (Peters et al., 2010), whereas others describe them as only found attached
362 within the upper layers of the biofilm (Harriott & Noverr, 2009). This disparity
363 could be explained by different experimental conditions (e.g. growth medium).
364 The initial colonising species plays a key role in dictating their interaction, as it
365 has been shown that *C. albicans* biofilm formation was delayed when *S.*
366 *aureus* colonised first, yet when added simultaneously biofilms formed rapidly
367 (Yi Jey Lin, 2013). The reason for this inhibition is unknown; perhaps *S.*
368 *aureus* secretes an inhibitory molecule preventing *Candida* adhesion.

369

370 Studies in *S. epidermidis* have shown that extracellular DNA (eDNA) release
371 through autolysis is an important entity in supporting mixed biofilm growth
372 (Pammi et al., 2013), and is a feature also critical for *C. albicans* biofilm
373 extracellular matrix (ECM) integrity (Rajendran et al., 2014, Sapaar et al.,
374 2014). Therefore, it is not surprising that eDNA and the ECM from both *C.*

375 *albicans* and *S. aureus* biofilms are both involved in affecting the action of
376 antibacterial agents. In fact, it has been shown that *S. aureus* is protected
377 against vancomycin treatment using concentrations as high as 1600mg/mL
378 within the mixed biofilm environment, through *C. albicans* ECM preventing
379 diffusion and access to *S. aureus* (Harriott & Noverr, 2009). There are,
380 however, other adaptive resistance mechanisms that play a role in this
381 resistance phenotype (Harriott & Noverr, 2010).

382

383 It has also been shown that *S. aureus* preferentially adhere to hyphal
384 filaments by relying on the adhesion to the *C. albicans* agglutinin-like
385 sequence 3 protein (Als3p) (Peters *et al.*, 2010, Peters *et al.*, 2012), though it
386 is likely that other proteins are involved. *S. epidermidis* have also been shown
387 to preferentially adhere to hyphae, with forces between single bacterial and
388 fungal germ tubes showing large adhesion forces (~5 nN) (Beaussart *et al.*,
389 2013). Studies have shown that *S. aureus* binding to *C. albicans* hyphae was
390 significantly stronger than all other bacteria tested, including *P. aeruginosa*
391 (Peters *et al.*, 2010). Interestingly, it was reported that none of the members
392 of the ALS family of adhesins, (ALS1-7 and ALS9), including ALS3, are
393 involved in interspecies adhesion (Harriott & Noverr, 2010). Thus further
394 insight is required before we can fully understand the mechanisms
395 responsible for adherence, yet it is likely that this is a complex process in
396 which a multitude of proteins are involved. Nevertheless, it is thought that
397 adhesion to hyphae may assist *S. aureus* in penetrating into the host
398 (Schlecht *et al.*, 2015), a manner analogous to injection from a needle-stick
399 injury. This has been demonstrated in mice studies, in which mixed infections
400 with *C. albicans als3Δ* strains together with *S. aureus* were unable to invade
401 the tongue, whereas the wild type infections demonstrated co-infection
402 (Peters *et al.*, 2012). The ramifications of this enhanced invasive capacity
403 have been shown historically to impact mortality, where synergism between
404 the co-infected species administered intraperitoneally in a mouse model, lead
405 to 100% mortality, whereas mono-species infections caused no mortality
406 whatsoever (Carlson, 1983). Whether or not the relationship between the two
407 organisms is physical or chemical remains to be determined, although there is

408 evidence that growth related synergy is an important factor in their co-
409 habitation of micro-niches (Carlson & Johnson, 1985). Indeed, the physical
410 relationship between the organisms is important, but not fundamental. Recent
411 studies indicated that morphogenesis, i.e. the presence of hyphae, is not
412 critical for their pathogenic potential, as demonstrated in some intricate
413 murine studies using *C. albicans* genetically locked into the yeast state (Nash
414 *et al.*, 2014). This suggests that physical cellular interactions are not solely
415 responsible.

416

417 Metabolic signalling between *C. albicans* and *S. aureus* may play an
418 important role in orchestrating this relationship. Chemically mediated
419 signalling in the form of quorum sensing (QS), could potentiate both positive
420 and negative interactions between these two microorganisms, which may
421 inadvertently impact clinical outcomes. *C. albicans* secretion of farnesol, a QS
422 molecule, decreases *S. aureus* biofilm formation, as well as increasing its
423 susceptibility to antibiotics (Akiyama *et al.*, 2002, Jabra-Rizk *et al.*, 2006,
424 Unnanuntana *et al.*, 2009). Moreover, it was shown to competitively inhibit *S.*
425 *aureus* lipase activity (Kuroda *et al.*, 2007). However, Lin *et al.* (2013) found
426 that *S. aureus* conditioned media had a striking impact on *C. albicans* biofilm
427 growth rate, indicating that *S. aureus* secretes a reciprocal quorum sensing
428 molecule that stimulates *C. albicans* growth (Lin *et al.*, 2013). Nonetheless,
429 whether *C. albicans* secretes sufficient farnesol *in vivo* to have an effect on *S.*
430 *aureus*, remains unknown. Yet despite these conflicting results, the majority of
431 studies support the idea of a synergistic relationship between the two.

432

433 Indeed, affinity panning of a *S. aureus* phage display library against *C.*
434 *albicans* biofilms demonstrated that *S. aureus* released extracellular
435 fibrinogen binding protein (Efb) during the interaction. This was shown to coat
436 *C. albicans* yeast cells and reduce phagocytosis by granulocytes (Fehrmann
437 *et al.*, 2013). In order to gain a better understanding of the molecular
438 interaction between *C. albicans* and *S. aureus*, Peters and colleagues (2010)
439 undertook a proteomics approach to identify proteins up-regulated during their
440 interaction (Peters *et al.*, 2010). The majority of the 27 proteins that were up-
441 regulated were involved in processes, including, stress and growth responses,

442 and metabolism. *S. aureus* up-regulated stress-related genes in response to
443 both yeast and hyphae, yet, interestingly most of these genes were up-
444 regulated in response to yeast rather than hyphal biofilms. As for *C. albicans*,
445 yeast cells increased a number of stress related proteins such as Tsa1p and
446 aconitate hydratase, yet *C. albicans* in hyphal formation showed minimal
447 changes in gene expression in response to *S. aureus*. These results suggest
448 that both organisms induce a stress response on their initial encounter with
449 one another, particularly whilst *Candida* exists in yeast form. However as they
450 mature and develop into a hyphal biofilm, they may down regulate these
451 genes as a survival strategy, facilitating survival within the host.

452

453 Clearly, these two pathogens have the ability to influence one another's
454 behaviour, so care must be taken in their clinical management. Broad-
455 spectrum antimicrobial activity is crucial, accounting for both prokaryote and
456 eukaryote. The use of ethanol has been shown to be effective at preventing
457 both mono-and poly-microbial biofilms (Peters *et al.*, 2013). However, the
458 successful use of miconazole in angular cheilitis is interesting given no
459 precise mechanism of action for this azole to *S. aureus* (Sud & Feingold,
460 1982). It could therefore be hypothesised that given the polymicrobiality of the
461 disease miconazole acts by exhibiting *C. albicans* activity, thereby
462 destabilising *S. aureus* colonisation, which is physically supported by the
463 hyphal biofilm meshwork. What is clear though is that these organisms are no
464 strangers to one another.

465

466 *Streptococcal interactions*

467 Streptococci are amongst the primary colonisers of the oral cavity and
468 compromise a large proportion of the overall flora (Syed & Loesche, 1978,
469 Moore *et al.*, 1982). Oral streptococcal species are often termed as the mitis
470 group streptococci (MGS), which include *S. mitis*, *S. oralis*, *S. gordonii*, *S.*
471 *sanguinis* and *S. parasanguinis* species (Kawamura *et al.*, 1995). MGS
472 streptococci are traditionally known to be early colonisers of dental surfaces,
473 comprising approximately 60-80% of the flora (Diaz *et al.*, 2012), although use
474 of high throughput gene sequencing technology has revealed them to also be
475 predominant colonisers of oral mucosal surfaces (Diaz *et al.*, 2012).

476

477 The relationship between *Candida* and streptococci is generally considered to
478 be synergistic, with advanced microscopy showing streptococcal interactions
479 with the hyphal filaments of *Candida* (Dutton *et al.*, 2014). Streptococci
480 provide *Candida* with nutrients from the salivary pellicle, such as lactate and
481 glucose, which *Candida* utilise as a source of carbon (Holmes *et al.*, 2006).
482 Furthermore, streptococci are aciduric and thus create an acid environment
483 through the fermentation of carbohydrates (Takahashi & Nyvad, 2011). At low
484 pH *Candida* grows in its yeast form. However, when co-colonised with
485 streptococci, *Candida* can grow and survive at a lower pH (<4.5), and the
486 H₂O₂ produced by streptococci can induce hyphal growth by inducing
487 oxidative stress (Jenkinson *et al.*, 1990, Nasution *et al.*, 2008). This
488 interaction is bidirectional, as *C. albicans* can promote the survival of
489 streptococci by lowering oxygen tension levels to that more acceptable for
490 streptococcal growth, as well as providing nutrients to stimulate bacterial
491 growth (Douglas, 2002). This synergistic relationship can prove disparaging
492 for the host. Studies have shown that streptococci augment the persistence of
493 *Candida* spp. Xu and colleagues (2014) demonstrated that co-infection with
494 *C. albicans* and *S. oralis* resulted in a more pathogenic inflammatory
495 response compared with infection with either microorganism alone, as
496 demonstrated through an exaggerated up-regulation of TLR2 dependant
497 inflammatory genes (Dutton *et al.*, 2014, Xu *et al.*, 2014).

498

499 Adherence to mucosal surfaces occurs through binding interactions with
500 components of the salivary pellicle, however, there is a limited number of
501 niches for *C. albicans* to inhabit. Thus, *C. albicans* has to compete with other
502 microbes (Kolenbrander *et al.*, 2002). To overcome this problem *C. albicans*
503 has evolved a mechanism allowing it to bind directly to MGS species, including
504 *S. oralis*, *S. mitis* and *S. gordonii* (Jenkinson *et al.*, 1990). This interaction is
505 mutually beneficial as *C. albicans* can support the outgrowth of streptococci by
506 enabling them to form more robust oral biofilms (Xu *et al.*, 2014). Adherence
507 between these two species occurs via interactions of the *C. albicans* hyphal
508 cell wall protein Als3, and the streptococcal cell surface adhesins SspA and
509 SspB (Holmes *et al.*, 1996), proteins that belong to the antigen I/II polypeptide

510 family (Bamford *et al.*, 2009). Als3p is one of eight Als protein family members
511 expressed in *C. albicans* (Als1p-7p, Als9p). Direct binding of SspB and Als3 is
512 required for bacterial-fungal attachment. Interaction between these molecules
513 is associated with the N-terminal domain of Als3 (Bamford *et al.*, 2015), as
514 deletions at the N-terminus abrogated binding to *S. gordonii*. Hoyer and
515 colleagues (2014) have demonstrated that this interaction may be more
516 complex than originally thought by showing that the peptide-binding domain
517 (PBD) of *C. albicans* is essential for *C. albicans*-*S. gordonii* adherence. The
518 PBD functions by binding to the free C-terminus, however, in *S. gordonii* the
519 SspB C-terminus is covalently linked to peptidoglycan, and is thus unavailable
520 to bind. Further investigation is required before we can fully understand the
521 mechanism behind this interaction, though recent studies suggest that the
522 early stage of cell wall O-mannosylation may be important in the development
523 of these polymicrobial communities (Dutton *et al.*, 2014).

524

525

526 An important component of a biofilm is the extracellular matrix (ECM), which
527 confers protection to antimicrobials (Xu *et al.*, 2014). The ECM of
528 streptococcal biofilms is composed of α -glucans (Gregoire *et al.*, 2011),
529 whereas *Candida* biofilm ECM is primarily composed of β -glucans (Al-Fattani
530 & Douglas, 2006, Taff *et al.*, 2012). *S. mutans* utilises its ECM components to
531 enhance adhesion to fungal cells by depositing α -glucans on the surface of
532 hyphae (Gregoire *et al.*, 2011). Moreover, interaction between *S. mutans* and
533 *C. albicans* is promoted by glucosyltransferase-derived ECM and expression
534 of the *S. mutans* virulence gene *gtfB* (Falsetta *et al.*, 2014). It was also shown
535 in this study that *Candida*-derived β 1,3-glucans contribute to ECM matrix
536 structure, whilst fungal β -glucan and mannan provide sites for GtfB binding
537 and activity. Furthermore, β -glucans are found on the surface of hyphae as
538 well as in the matrix (Dongari-Bagtzoglou *et al.*, 2009), thus suggesting that
539 streptococci utilise these proteins to adhere to candidal hyphae. Collectively,
540 this suggests the biofilm ECM contributes to this mutualistic behavior,
541 favouring their co-existence in the oral environment to the detriment of the host.

542

543 As with *Candida* – *S. aureus* interactions, quorum sensing (QS), is an
544 important factor in the relationship between *Candida* and streptococci.
545 Farnesol, a tetraprenoid alcohol and a key intermediate in the sterol
546 biosynthetic pathway in eukaryotic cells, represents the primary QS molecule
547 associated with *C. albicans*, its main role being repression of hyphal growth
548 and biofilm formation (Ramage *et al.*, 2002). However, one study has
549 suggested that *S. gordonii* is able to suppress farnesol induced inhibition of
550 biofilm formation, via autoinducer 2 (AI-2), as *luxS* mutants were less effective
551 at permitting hyphal formation, however the mode of action has yet to be
552 elucidated (Bamford *et al.*, 2009). Farnesol has also been shown to inhibit *S.*
553 *mutans* biofilm accumulation and polysaccharide production (Koo *et al.*,
554 2003). Based on this and further work, it has been suggested that it may be
555 used to control its competitiveness in mixed species biofilms and could be
556 used as a means of a chemotherapeutic strategy (Jeon *et al.*, 2011). AI-2 is
557 the primary QS molecule secreted by bacteria that allows inter-species
558 communication (Vendeville *et al.*, 2005). The *luxS* gene is associated with AI-
559 2 production and *luxS* streptococcal mutants can form monospecies biofilms.
560 However, when co-colonised with *C. albicans*, biofilm formation becomes
561 abrogated, suggesting this molecule is involved in cellular communication
562 (McNab *et al.*, 2003, Bamford *et al.*, 2009). Another important signalling
563 mechanism in streptococci, including *S. gordonii*, is through the comCDE
564 operon, which encodes a sensor-regulator system (ComDE) activated by the
565 comC gene product competence stimulating peptide (CSP). *S. gordonii*-*C.*
566 *albicans* biofilms formed with Δ comCDE or Δ comC mutants showed
567 increased biomass compared to wild-type biofilms. Interestingly, more eDNA
568 was observed in the mixed Δ comCDE mutant biofilms. Although purified CSP
569 did not affect *C. albicans* hyphal formation. Contrary to earlier findings (Jarosz
570 *et al.*, 2009), it did inhibit monospecies biofilm formation, suggesting that the *S.*
571 *gordonii* comCDE QS-system modulates the production of eDNA (Jack *et al.*,
572 2015), and important component of candidal ECM (Rajendran *et al.*, 2014).
573
574 *Candidal interactions*
575 Hyphae provide *C. albicans* with an advantage over many of its competitors in
576 terms of size and surface area, enabling them to take advantage of more sites

577 for adhesion and occupation of a variety of niches. This is why it is a more
578 successful pathogen than other members of the genus. Nonetheless, there is
579 hypothesis that *Candida spp.*, in particular *C. glabrata* benefit from *C.*
580 *albicans*. There have been suggestions that DS pathology may be promoted
581 by the synergistic interaction between these species within denture biofilms.
582 Coco and colleagues (2008) first reported that *C. glabrata* and *C. albicans*
583 were often co-isolated from patients, particularly those with severe
584 inflammation. The authors hypothesised that pathogenic synergy existed
585 between the two *Candida* species. *C. glabrata*, devoid of hyphae, forms
586 relatively structurally poor and unstable biofilms, yet is associated with
587 disease. Therefore, it was hypothesised to use *C. albicans* as a structural
588 scaffold to gain entry into the host. Further studies have confirmed this, where
589 *C. albicans* appeared to assist the invasive capacity of *C. glabrata* within an *in*
590 *vitro* reconstituted epithelial biofilm model (Silva *et al.*, 2011). The mechanistic
591 of this interaction are at present unknown, however we can speculate that
592 tissue destruction through proteolytic and lipolytic enzymes augments the
593 invasive capacity of the hyphae and allows co-aggregative *C. glabrata* to
594 enter and contribute to pathogenesis. Further work by this group has shown
595 similar data with work in a reconstituted human vaginal epithelial model,
596 where *C. glabrata* individually caused minimal tissue damage, though there
597 was a significant increase in *C. glabrata* colonisation and invasiveness in
598 combination with *C. albicans* (Alves *et al.*, 2014). Damage was primarily
599 dependent on the process of invasion, with key virulence genes upregulated
600 (*HWP1*, *PLD1* and *ALS3*). Further studies using *in vivo* models to investigate
601 the pathogenesis of denture stomatitis would be useful in this context (Nett *et*
602 *al.*, 2010), although as described above there is mounting evidence that
603 hitchhiking through adhesion to hyphae is not a limited phenomenon and may
604 also be important with respect to *C. glabrata* using *C. albicans* to gain entry to
605 the host (Schlecht *et al.*, 2015).

606

607 *Anaerobic Gram-negative interactions*

608 Life in subgingival plaque is highly anaerobic, favouring many obligate PD
609 pathogens such as *P. gingivalis*, *F. nucleatum* and *P. intermedia*. However,
610 given the undefined relationship between *Candida spp* and PD, then this

611 remains a relatively neglected area of research. Studies regarding *C. albicans*
612 and *P. gingivalis* have produced conflicting results. It was shown that *P.*
613 *gingivalis* suppressed *Candida* biofilm formation through a reduction in the
614 number of viable yeast cells coincidental with an increasing *P. gingivalis*
615 concentration (Thein *et al.*, 2006). Conversely, it was also shown that *P.*
616 *gingivalis* induces germ-tube formation in *C. albicans*, producing a more
617 invasive phenotype, thus increasing the risk of infection (Nair *et al.*, 2001).
618 Furthermore, both microbes appear to have an antagonistic effect on one
619 another in relation to host cell adhesion, as *P. gingivalis* inhibited adhesion of
620 *C. albicans* to buccal epithelial cells (Nair & Samaranayake, 1996), whilst the
621 presence of *C. albicans* did not enhance adhesion to gingival epithelial cells
622 or gingival fibroblasts by *P. gingivalis* (Tamai *et al.*, 2011). Yet, in the same
623 study pre-exposure of gingival epithelial cells and fibroblasts to *C. albicans*
624 enhanced cell invasion by *P. gingivalis*. Clearly, further studies are required to
625 decipher how these microorganisms interact with one another.

626

627 As for *F. nucleatum*, co-aggregation studies have revealed its ability to adhere
628 to *C. albicans* species (Grimaudo & Nesbitt, 1997), as well as *C. dubliniensis*
629 (Jabra-Rizk *et al.*, 1999). However, the interaction with *C. albicans* may be
630 temperature dependant as *C. albicans* grown at 37°C did not co-aggregate
631 with *F. nucleatum*, yet the two species did co-aggregate when grown at 25°C
632 and 45°C (Jabra-Rizk *et al.*, 1999). The exact mechanistic behind these
633 interactions remain unknown, however these observations indicate *C.*
634 *albicans*- *F. nucleatum* interactions may be an important factor in oral
635 colonisation by yeasts.

636

637 Studies using lipopolysaccharide (LPS) from a variety of Gram-negative
638 strains have shown that hyphal formation is inhibited as is biofilm formation in
639 a number of *Candida spp.* (Bandara *et al.*, 2010), indicating that physical
640 interaction may be an important factor in defining their subgingival niches.
641 Subsequent work in *Escherichia coli* demonstrated that secreted elements
642 also play an important role in affecting hyphal formation (Bandara *et al.*,
643 2013). This is also true of the relationship between the capnophilic bacterium
644 *A. actinomycetemcomitans* where it has been shown that its release of AI-2

645 was actively involved in inhibiting *C. albicans* hyphal growth and biofilm
646 formation (Bachtiar *et al.*, 2014). Given the complexity of various metabolites
647 and QS molecules in subgingival plaque, such as volatile sulphur compounds,
648 fatty acids and AI-2 (Kurita-Ochiai *et al.*, 1995, Huang *et al.*, 2011, Jang *et al.*,
649 2013, Basic & Dahlen, 2014), it is likely these also impact hyphal formation
650 and *Candida*'s ability to contribute to PD (Noverr & Huffnagle, 2004). This
651 anoxic environment has been shown to result in significant transcriptional
652 changes in *C. albicans*, including the upregulation of *WOR1*, which is a
653 transcriptional regulator central to phenotypic switching (Fox *et al.*, 2014).
654 Based on the available literature it could be surmised that subgingival plaque
655 is most likely to antagonise yeast proliferation, except in cases where there is
656 dysbiosis of the biofilm ecology, such as following broad-spectrum antibiotic
657 therapy or pre-existing medical conditions, including diabetes (Rams *et al.*,
658 1990, Sardi *et al.*, 2010, Al Mubarak *et al.*, 2013).

659

660 *Facultative Gram-positive interactions*

661 *Candida* species and *E. faecalis* have become increasingly noted for their co-
662 isolation within endodontic infections, both of which play an important role in
663 nosocomial infection. Interestingly, data from a longitudinal study carried out
664 over two years at a German teaching hospital found that *Candida* positive
665 patients (blood, CSF, skin, feaces or sputum) were twice as likely to be co-
666 colonised by *E. faecalis* (Hermann *et al.*, 1999). *E. faecalis* has been found to
667 incorporate itself into *Candida* biofilms, and is the third most predominant
668 bacterial spp. found in mucosal fungal biofilms (Dongari-Bagtzoglou *et al.*,
669 2009, Fox *et al.*, 2014). It was shown to adhere to *Candida* in both hyphal and
670 yeast forms, yet caused a reduction in the overall biofilm biomass (Fox *et al.*,
671 2014). However, Cruz and colleagues (2013) demonstrated that *E. faecalis*
672 inhibited hyphal morphogenesis, which was partially dependent on the *Fsr*
673 quorum-sensing system, a major regulator of *E. faecalis* virulence (Cruz *et al.*,
674 2013). Collectively, these effects both impacted virulence during co-infection
675 when compared to mono-species infection, suggesting that they both
676 negatively influence one another's virulence and help maintain a commensal
677 relationship (Garsin & Lorenz, 2013). Further work has revealed that *C.*
678 *albicans* releases a surface protein Msb2, which binds to host antimicrobial

679 peptides as well as antibiotics, thus conferring protection to both organisms
680 (Swidergall *et al.*, 2013). Furthermore, evaluating the influence of *C. albicans*
681 on the dynamics of the bacterial microbiome following antibiotic treatment
682 found that bacterial re-colonisation was enhanced in the presence of *C.*
683 *albicans* (Mason *et al.*, 2012). Moreover, *C. albicans* reduced *Lactobacillus*
684 spp. whilst enhancing *E. faecalis* numbers, which led to the persistence of *E.*
685 *faecalis* long term. This effect was not apparent in subjects when *C. albicans*
686 was absent. Whether this effect was due to a synergistic relationship with *E.*
687 *faecalis* or an antagonistic interaction with lactobacilli remains to be elucidated.
688

689 There is a conceived dogma that lactobacilli antagonise candidal colonisation
690 (Young *et al.*, 1956). This forms the basis of why they play a key role in
691 probiotics. It is well documented that probiotics reduces candidal levels at
692 several sites, including oral cavity, bloodstream and urinary tract (Mendonca
693 *et al.*, 2012, Kumar *et al.*, 2013). Early observations indicate that *C. albicans*
694 decreased in the presence of lactobacilli through provision of nutrients for
695 lactobacilli that leads to lactic acid production, thus hindering candidal growth
696 through pH dependant inhibition. This dynamic relationship suggests that
697 there is a close association between the two, but to date this has mainly been
698 observed in vaginal infection. Our own microbiome studies of the denture
699 plaque have shown that *C. albicans* and lactobacilli are positively associated
700 in disease (unpublished work). The role of lactobacilli in maintaining
701 homeostasis at the vaginal mucosa initially came to light due to the
702 occurrence of vaginal candidiasis during treatment with systemic antibiotics.
703 The mechanisms by which *Lactobacillus* species inhibits growth and virulence
704 of *Candida* spp. are not yet fully understood, but perhaps the production of
705 hydrogen peroxide as it has been shown to cause anti-candidal activity, albeit
706 in some strains of lactobacilli (Strus *et al.*, 2005). This suggests that other
707 interactive mechanisms are involved in disease, including the modulation of
708 the host response whereby lactobacilli cells have been shown to up-regulate
709 inflammatory cytokines when co-cultured with *C. albicans* (Martinez *et al.*,
710 2009), potentially assisting in the clearance of candidal infection. Despite the
711 overwhelming evidence of an antagonistic interaction, certain species of oral
712 *Lactobacillus*, namely *L. casei*, have demonstrated a stimulatory effect on *C.*

713 *albicans* hyphal growth (Orsi *et al.*, 2014), and in fact it has been
714 demonstrated that candidal hyphae have the capacity to co-aggregate and
715 support lactobacilli levels in patients with higher levels of oral disease (Bilhan
716 *et al.*, 2009). Nevertheless, further studies are required to investigate these
717 interactions in detail to determine the true extent of the dynamic relationship;
718 particularly as the conceived antagonism may only exist for *C. albicans*. For
719 example, recent studies have shown that only one of six probiotic
720 *Lactobacillus* species had an inhibitory effect on *C. glabrata* growth (Jiang *et*
721 *al.*, 2015). This suggests that the interaction between *Candida* and lactobacilli
722 may be dependant on the particular environment they co-habit.

723

724 **Conclusions**

725 Collectively, these data demonstrate that the interaction between candidal
726 species and other microorganisms may be dependant on the nature of the
727 interaction (chemical, physical, or both) and the particular environment they
728 cohabit. It is clear from many of these studies that the interaction between *C.*
729 *albicans* hyphae and different bacterial species is important in defining their
730 interaction, whether mutualistic or antagonistic in nature. The secretion of
731 signalling molecules from the myriad of microorganisms in the oral cavity,
732 such as AI-2, farnesol, and other small molecules is clearly important, with
733 recent studies supporting the notion that the metabolome plays an integral
734 part in defining the interaction between the host, *Candida* and microbiota such
735 as lactobacilli (Romani *et al.*, 2015). Understanding how each of these
736 specific interactions influences one another and *Candida's* pathogenicity will
737 enable us to target this medically important yeast rationally. Though, we must
738 be cognisant of the negative influences of changing its role within complex
739 oral biofilm communities and the consequences of dysbiosis (McLean, 2014),
740 as this may support the unnecessary proliferation and overgrowth of candidal
741 yeasts that leads to oral disease.

742

743

744

745

746 **References**

- 747 Adam B, Baillie GS & Douglas LJ (2002) Mixed species biofilms of *Candida*
748 *albicans* and *Staphylococcus epidermidis*. *Journal of medical microbiology* **51**:
749 344-349.
- 750 Ader F, Jawhara S, Nseir S, Kipnis E, Faure K, Vuotto F, Chemani C, Sendid
751 B, Poulain D & Guery B (2011) Short term *Candida albicans* colonization
752 reduces *Pseudomonas aeruginosa*-related lung injury and bacterial burden in
753 a murine model. *Critical Care (London, England)* **15**: R150.
- 754 Akiyama H, Oono T, Huh WK, Yamasaki O, Ogawa S, Katsuyama M,
755 Ichikawa H & Iwatsuki K (2002) Actions of farnesol and xylitol against
756 *Staphylococcus aureus*. *Chemotherapy* **48**: 122-128.
- 757 Al-Fattani MA & Douglas LJ (2006) Biofilm matrix of *Candida albicans* and
758 *Candida tropicalis*: chemical composition and role in drug resistance. *Journal*
759 *of Medical Microbiology* **55**: 999-1008.
- 760 Al Mubarak S, Robert AA, Baskaradoss JK, Al-Zoman K, Al Sohail A,
761 Alsuwyyed A & Ciancio S (2013) The prevalence of oral *Candida* infections in
762 periodontitis patients with type 2 diabetes mellitus. *Journal of Infection and*
763 *Public Health* **6**: 296-301.
- 764 Alves CT, Wei XQ, Silva S, Azeredo J, Henriques M & Williams DW (2014)
765 *Candida albicans* promotes invasion and colonisation of *Candida glabrata* in a
766 reconstituted human vaginal epithelium. *The Journal of Infection* **69**: 396-407.
- 767 Arslan SG, Akpolat N, Kama JD, Ozer T & Hamamci O (2008) One-year
768 follow-up of the effect of fixed orthodontic treatment on colonization by oral
769 *Candida*. *J Oral Pathol Med* **37**: 26-29.
- 770 Bachtiar EW, Bachtiar BM, Jarosz LM, Amir LR, Sunarto H, Ganin H, Meijler
771 MM & Krom BP (2014) Al-2 of *Aggregatibacter actinomycetemcomitans*
772 inhibits *Candida albicans* biofilm formation. *Frontiers in Cellular and Infection*
773 *Microbiology* **4**: 94.
- 774 Badet C & Thebaud NB (2008) Ecology of lactobacilli in the oral cavity: a
775 review of literature. *Open Microbiol J* **2**: 38-48.
- 776 Baena-Monroy T, Moreno-Maldonado V, Franco-Martinez F, Aldape-Barrios B,
777 Quindos G & Sanchez-Vargas LO (2005) *Candida albicans*, *Staphylococcus*
778 *aureus* and *Streptococcus mutans* colonization in patients wearing dental
779 prosthesis. *Medicina Oral, Patologia Oral y Cirugia Bucal* **10 Suppl 1**: E27-39.
- 780 Bagg J, Sweeney MP, Lewis MA, Jackson MS, Coleman D, Al MA, Baxter W,
781 McEndrick S & McHugh S (2003) High prevalence of non-albicans yeasts and
782 detection of anti-fungal resistance in the oral flora of patients with advanced
783 cancer. *Palliat Med* **17**: 477-481.
- 784 Bamford CV, Nobbs AH, Barbour ME, Lamont RJ & Jenkinson HF (2015)
785 Functional regions of *Candida albicans* hyphal cell wall protein Als3 that

- 786 determine interaction with the oral bacterium *Streptococcus gordonii*.
787 *Microbiology* **161**: 18-29.
- 788 Bamford CV, d'Mello A, Nobbs AH, Dutton LC, Vickerman MM & Jenkinson
789 HF (2009) *Streptococcus gordonii* modulates *Candida albicans* biofilm
790 formation through intergeneric communication. *Infection and Immunity* **77**:
791 3696-3704.
- 792 Bandara HM, Lam OL, Watt RM, Jin LJ & Samaranayake LP (2010) Bacterial
793 lipopolysaccharides variably modulate in vitro biofilm formation of *Candida*
794 species. *Journal of Medical Microbiology* **59**: 1225-1234.
- 795 Bandara HM, Cheung BP, Watt RM, Jin LJ & Samaranayake LP (2013)
796 Secretory products of *Escherichia coli* biofilm modulate *Candida* biofilm
797 formation and hyphal development. *Journal of Investigative and Clinical*
798 *dentistry* **4**: 186-199.
- 799 Bandara HM, BP KC, Watt RM, Jin LJ & Samaranayake LP (2013)
800 *Pseudomonas aeruginosa* lipopolysaccharide inhibits *Candida albicans*
801 hyphae formation and alters gene expression during biofilm development.
802 *Molecular Oral Microbiology* **28**: 54-69.
- 803 Bansal M, Khatri M & Taneja V (2013) Potential role of periodontal infection in
804 respiratory diseases - a review. *Journal of Medicine and Life* **6**: 244-248.
- 805 Basic A & Dahlen G (2014) Hydrogen sulfide production from subgingival
806 plaque samples. *Anaerobe*. E-pub ahead of press.
- 807 Baumgartner JC, Watts CM & Xia T (2000) Occurrence of *Candida albicans* in
808 infections of endodontic origin. *Journal of Endodontics* **26**: 695-698.
- 809 Bauters TG, Moerman M, Vermeersch H & Nelis HJ (2002) Colonization of
810 voice prostheses by albicans and non-albicans *Candida* species. *The*
811 *Laryngoscope* **112**: 708-712.
- 812 Beaussart A, Herman P, El-Kirat-Chatel S, Lipke PN, Kucharikova S, Van
813 Dijck P & Dufrene YF (2013) Single-cell force spectroscopy of the medically
814 important *Staphylococcus epidermidis*-*Candida albicans* interaction.
815 *Nanoscale* **5**: 10894-10900.
- 816 Belda-Ferre P, Alcaraz LD, Cabrera-Rubio R, Romero H, Simon-Soro A,
817 Pignatelli M & Mira A (2012) The oral metagenome in health and disease.
818 *ISME J* **6**: 46-56.
- 819 Bertolini MM, Xu H, Sobue T, Nobile CJ, Del Bel Cury AA & Dongari-
820 Bagtzoglou A (2015) *Candida*-streptococcal mucosal biofilms display distinct
821 structural and virulence characteristics depending on growth conditions and
822 hyphal morphotypes. *Molecular Oral Microbiology*. E-pub ahead of press.
- 823 Bilhan H, Sulun T, Erkose G, Kurt H, Erturan Z, Kutay O & Bilgin T (2009) The
824 role of *Candida albicans* hyphae and *Lactobacillus* in denture-related
825 stomatitis. *Clinical Oral Investigations* **13**: 363-368.

- 826 Biswas D, Agarwal S, Sindhvani G & Rawat J (2010) Fungal colonization in
827 patients with chronic respiratory diseases from Himalayan region of India.
828 *Annals of Clinical Microbiology and Antimicrobials* **9**: 28.
- 829 Brusca MI, Rosa A, Albaina O, Moragues MD, Verdugo F & Ponton J (2010)
830 The impact of oral contraceptives on women's periodontal health and the
831 subgingival occurrence of aggressive periodontopathogens and *Candida*
832 species. *Journal of Periodontology* **81**: 1010-1018.
- 833 Buijssen KJ, Harmsen HJ, van der Mei HC, Busscher HJ & van der Laan BF
834 (2007) Lactobacilli: important in biofilm formation on voice prostheses.
835 *Otolaryngology-Head and Neck Surgery* **137**: 505-507.
- 836 Busscher HJ, Geertsema-Doornbusch GI & van der Mei HC (1997) Adhesion
837 to silicone rubber of yeasts and bacteria isolated from voice prostheses:
838 influence of salivary conditioning films. *Journal of Biomedical Materials*
839 *Research* **34**: 201-209.
- 840 Canabarro A, Valle C, Farias MR, Santos FB, Lazera M & Wanke B (2012)
841 Association of subgingival colonization of *Candida albicans* and other yeasts
842 with severity of chronic periodontitis. *J Periodontal Res.*
- 843 Carlson E (1983) Effect of strain of *Staphylococcus aureus* on synergism with
844 *Candida albicans* resulting in mouse mortality and morbidity. *Infection and*
845 *Immunity* **42**: 285-292.
- 846 Carlson E & Johnson G (1985) Protection by *Candida albicans* of
847 *Staphylococcus aureus* in the establishment of dual infection in mice. *Infection*
848 *and immunity* **50**: 655-659.
- 849 Coco BJ, Bagg J, Cross LJ, Jose A, Cross J & Ramage G (2008) Mixed
850 *Candida albicans* and *Candida glabrata* populations associated with the
851 pathogenesis of denture stomatitis. *Oral Microbiology and Immunology* **23**:
852 377-383.
- 853 Coleman D, Sullivan D, Harrington B, Haynes K, Henman M, Shanley D,
854 Bennett D, Moran G, McCreary C & O'Neill L (1997) Molecular and phenotypic
855 analysis of *Candida dubliniensis*: a recently identified species linked with oral
856 candidosis in HIV-infected and AIDS patients. *Oral Dis* **3 Suppl 1**: S96-101.
- 857 Coulthwaite L & Verran J (2007) Potential pathogenic aspects of denture
858 plaque. *British Journal of Biomedical Science* **64**: 180-189.
- 859 Cruz MR, Graham CE, Gagliano BC, Lorenz MC & Garsin DA (2013)
860 *Enterococcus faecalis* inhibits hyphal morphogenesis and virulence of
861 *Candida albicans*. *Infection and Immunity* **81**: 189-200.
- 862 Cunha-Cruz J, Hujoel PP & Nadanovsky P (2007) Secular trends in socio-
863 economic disparities in edentulism: USA, 1972-2001. *Journal of Dental*
864 *Research* **86**: 131-136.

- 865 Dagistan S, Aktas AE, Caglayan F, Ayyildiz A & Bilge M (2009) Differential
866 diagnosis of denture-induced stomatitis, *Candida*, and their variations in
867 patients using complete denture: a clinical and mycological study. *Mycoses*
868 **52**: 266-271.
- 869 Darwazeh AM, Hammad MM & Al-Jamaei AA (2010) The relationship
870 between oral hygiene and oral colonization with *Candida* species in healthy
871 adult subjects*. *International Journal of Dental Hygiene* **8**: 128-133.
- 872 de Carvalho FG, Silva DS, Hebling J, Spolidorio LC & Spolidorio DM (2006)
873 Presence of mutans streptococci and *Candida* spp. in dental plaque/dentine
874 of carious teeth and early childhood caries. *Arch Oral Biol* **51**: 1024-1028.
- 875 Diaz PI, Dupuy AK, Abusleme L, Reese B, Oberfell C, Choquette L, Dongari-
876 Bagtzoglou A, Peterson DE, Terzi E & Strausbaugh LD (2012) Using high
877 throughput sequencing to explore the biodiversity in oral bacterial
878 communities. *Molecular Oral Microbiology* **27**: 182-201.
- 879 Dongari-Bagtzoglou A, Kashleva H, Dwivedi P, Diaz P & Vasilakos J (2009)
880 Characterization of mucosal *Candida albicans* biofilms. *PLoS One* **4**: e7967.
- 881 Douglas HFJaLJ (2002) Interactions between *Candida* species and bacteria in
882 mixed infections. *Polymicrobial Diseases*, Chapter 18. ASM Press,
883 Washington (DC).
- 884 Dutton LC, Nobbs AH, Jepson K, Jepson MA, Vickerman MM, Aqeel Alawfi S,
885 Munro CA, Lamont RJ & Jenkinson HF (2014) O-mannosylation in *Candida*
886 *albicans* enables development of interkingdom biofilm communities. *mBio* **5**:
887 e00911.
- 888 Eke PI, Dye BA, Wei L, Thornton-Evans GO & Genco RJ (2012) Prevalence
889 of periodontitis in adults in the United States: 2009 and 2010. *Journal of*
890 *Dental Research* **91**: 914-920.
- 891 El-Solh AA (2011) Association between pneumonia and oral care in nursing
892 home residents. *Lung* **189**: 173-180.
- 893 Falsetta ML, Klein MI, Colonne PM, *et al.* (2014) Symbiotic relationship
894 between *Streptococcus mutans* and *Candida albicans* synergizes virulence of
895 plaque biofilms in vivo. *Infection and Immunity* **82**: 1968-1981.
- 896 Fehrmann C, Jurk K, Bertling A, Seidel G, Fegeler W, Kehrel BE, Peters G,
897 Becker K & Heilmann C (2013) Role for the fibrinogen-binding proteins
898 coagulase and Efb in the *Staphylococcus aureus-Candida* interaction.
899 *International Journal of Medical Microbiology : IJMM* **303**: 230-238.
- 900 Fox EP, Cowley ES, Nobile CJ, Hartooni N, Newman DK & Johnson AD
901 (2014) Anaerobic bacteria grow within *Candida albicans* biofilms and induce
902 biofilm formation in suspension cultures. *Current Biology : CB* **24**: 2411-2416.

- 903 Freitas AO, Marquezan M, Nojima Mda C, Alviano DS & Maia LC (2014) The
904 influence of orthodontic fixed appliances on the oral microbiota: a systematic
905 review. *Dental Press Journal of Orthodontics* **19**: 46-55.
- 906 Garsin DA & Lorenz MC (2013) *Candida albicans* and *Enterococcus faecalis*
907 in the gut: synergy in commensalism? *Gut Microbes* **4**: 409-415.
- 908 Gendreau L & Loewy ZG (2011) Epidemiology and etiology of denture
909 stomatitis. *Journal of Prosthodontics* **20**: 251-260.
- 910 Gleeson K, Egli DF & Maxwell SL (1997) Quantitative aspiration during sleep
911 in normal subjects. *Chest* **111**: 1266-1272.
- 912 Gregoire S, Xiao J, Silva BB, et al. (2011) Role of glucosyltransferase B in
913 interactions of *Candida albicans* with *Streptococcus mutans* and with an
914 experimental pellicle on hydroxyapatite surfaces. *Appl Environ Microbiol* **77**:
915 6357-6367.
- 916 Grimaudo NJ & Nesbitt WE (1997) Coaggregation of *Candida albicans* with
917 oral *Fusobacterium* species. *Oral Microbiology and Immunology* **12**: 168-173.
- 918 Guo L & Shi W (2013) Salivary biomarkers for caries risk assessment. *Journal*
919 *of the California Dental Association* **41**: 107-109, 112-108.
- 920 Haffajee AD & Socransky SS (2006) Introduction to microbial aspects of
921 periodontal biofilm communities, development and treatment. *Periodontology*
922 *2000* **42**: 7-12.
- 923 Hammad MM, Darwazeh AM & Idrees MM (2013) The effect of glycemic
924 control on *Candida* colonization of the tongue and the subgingival plaque in
925 patients with type II diabetes and periodontitis. *Oral surgery, oral medicine,*
926 *oral pathology and oral radiology* **116**: 321-326.
- 927 Harriott MM & Noverr MC (2009) *Candida albicans* and *Staphylococcus*
928 *aureus* form polymicrobial biofilms: effects on antimicrobial resistance.
929 *Antimicrobial Agents and Chemotherapy* **53**: 3914-3922.
- 930 Harriott MM & Noverr MC (2010) Ability of *Candida albicans* mutants to
931 induce *Staphylococcus aureus* vancomycin resistance during polymicrobial
932 biofilm formation. *Antimicrobial Agents and Chemotherapy* **54**: 3746-3755.
- 933 Hermann C, Hermann J, Munzel U & Ruchel R (1999) Bacterial flora
934 accompanying *Candida* yeasts in clinical specimens. *Mycoses* **42**: 619-627.
- 935 Hogan DA & Kolter R (2002) *Pseudomonas-Candida* interactions: an
936 ecological role for virulence factors. *Science* **296**: 2229-2232.
- 937 Hogan DA, Vik A & Kolter R (2004) A *Pseudomonas aeruginosa* quorum-
938 sensing molecule influences *Candida albicans* morphology. *Molecular*
939 *Microbiology* **54**: 1212-1223.

- 940 Holmes AR, Cannon RD & Jenkinson HF (1995) Interactions of *Candida*
941 *albicans* with bacteria and salivary molecules in oral biofilms. *Journal of*
942 *Industrial Microbiology* **15**: 208-213.
- 943 Holmes AR, McNab R & Jenkinson HF (1996) *Candida albicans* binding to the
944 oral bacterium *Streptococcus gordonii* involves multiple adhesin-receptor
945 interactions. *Infection and Immunity* **64**: 4680-4685.
- 946 Holmes AR, van der Wielen P, Cannon RD, Ruske D & Dawes P (2006)
947 *Candida albicans* binds to saliva proteins selectively adsorbed to silicone.
948 *Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, and*
949 *Endodontics* **102**: 488-494.
- 950 Holmstrup P (1999) Non-plaque-induced gingival lesions. *Annals of*
951 *periodontology / the American Academy of Periodontology* **4**: 20-31.
- 952 Huang CB, Alimova Y, Myers TM & Ebersole JL (2011) Short- and medium-
953 chain fatty acids exhibit antimicrobial activity for oral microorganisms. *Arch*
954 *Oral Biol* **56**: 650-654.
- 955 Jabra-Rizk MA, Meiller TF, James CE & Shirliff ME (2006) Effect of farnesol
956 on *Staphylococcus aureus* biofilm formation and antimicrobial susceptibility.
957 *Antimicrobial Agents and Chemotherapy* **50**: 1463-1469.
- 958 Jabra-Rizk MA, Falkler WA, Jr., Merz WG, Kelley JI, Baqui AA & Meiller TF
959 (1999) Coaggregation of *Candida dubliniensis* with *Fusobacterium nucleatum*.
960 *Journal of Clinical Microbiology* **37**: 1464-1468.
- 961 Jack AA, Daniels DE, Jepson MA, Vickerman MM, Lamont RJ, Jenkinson HF
962 & Nobbs AH (2015) *Streptococcus gordonii* comCDE (competence) operon
963 modulates biofilm formation with *Candida albicans*. *Microbiology* **161**: 411-421.
- 964 Jang YJ, Choi YJ, Lee SH, Jun HK & Choi BK (2013) Autoinducer 2 of
965 *Fusobacterium nucleatum* as a target molecule to inhibit biofilm formation of
966 periodontopathogens. *Arch Oral Biol* **58**: 17-27.
- 967 Jarosz LM, Deng DM, van der Mei HC, Crielaard W & Krom BP (2009)
968 *Streptococcus mutans* competence-stimulating peptide inhibits *Candida*
969 *albicans* hypha formation. *Eukaryotic Cell* **8**: 1658-1664.
- 970 Jeganathan S & Lin CC (1992) Denture stomatitis-a review of the aetiology,
971 diagnosis and management. *Australian Dental Journal* **37**: 107-114.
- 972 Jenkinson HF, Lala HC & Shepherd MG (1990) Coaggregation of
973 *Streptococcus sanguis* and other streptococci with *Candida albicans*. *Infection*
974 *and Immunity* **58**: 1429-1436.
- 975 Jeon JG, Pandit S, Xiao J, Gregoire S, Falsetta ML, Klein MI & Koo H (2011)
976 Influences of trans-trans farnesol, a membrane-targeting sesquiterpenoid, on
977 *Streptococcus mutans* physiology and survival within mixed-species oral
978 biofilms. *International Journal of Oral Science* **3**: 98-106.

- 979 Jiang Q, Stamatova I, Kari K & Meurman JH (2015) Inhibitory activity in vitro
980 of probiotic lactobacilli against oral *Candida* under different fermentation
981 conditions. *Beneficial Microbes* **6**: 361-368.
- 982 Kawamura Y, Hou XG, Sultana F, Miura H & Ezaki T (1995) Determination of
983 16S rRNA sequences of *Streptococcus mitis* and *Streptococcus gordonii* and
984 phylogenetic relationships among members of the genus *Streptococcus*.
985 *International Journal of Systematic Bacteriology* **45**: 406-408.
- 986 Kazi YF, Saleem S & Kazi N (2012) Investigation of vaginal microbiota in
987 sexually active women using hormonal contraceptives in Pakistan. *BMC*
988 *urology* **12**: 22.
- 989 Kolenbrander PE, Andersen RN, Blehert DS, Eglund PG, Foster JS & Palmer
990 RJ, Jr. (2002) Communication among oral bacteria. *Microbiology and*
991 *Molecular Biology Reviews: MMBR* **66**: 486-505.
- 992 Koo H & Bowen WH (2014) *Candida albicans* and *Streptococcus mutans*: a
993 potential synergistic alliance to cause virulent tooth decay in children. *Future*
994 *Microbiology* **9**: 1295-1297.
- 995 Koo H, Hayacibara MF, Schobel BD, Cury JA, Rosalen PL, Park YK, Vacca-
996 Smith AM & Bowen WH (2003) Inhibition of *Streptococcus mutans* biofilm
997 accumulation and polysaccharide production by apigenin and tt-farnesol. *The*
998 *Journal of Antimicrobial Chemotherapy* **52**: 782-789.
- 999 Kraneveld EA, Buijs MJ, Bonder MJ, Visser M, Keijser BJ, Crielaard W &
1000 Zaura E (2012) The relation between oral *Candida* load and bacterial
1001 microbiome profiles in Dutch older adults. *PLoS One* **7**: e42770.
- 1002 Krasse B (1954) The relationship between lactobacilli, *Candida* and
1003 streptococci and dental caries; examination of saliva and plaque material
1004 collected on the same occasion. *Odontologisk Revy* **5**: 241-261.
- 1005 Kumar S, Singhi S, Chakrabarti A, Bansal A & Jayashree M (2013) Probiotic
1006 use and prevalence of candidemia and candiduria in a PICU. *Pediatric Critical*
1007 *Care Medicine* **14**: e409-415.
- 1008 Kurita-Ochiai T, Fukushima K & Ochiai K (1995) Volatile fatty acids, metabolic
1009 by-products of periodontopathic bacteria, inhibit lymphocyte proliferation and
1010 cytokine production. *Journal of Dental Research* **74**: 1367-1373.
- 1011 Kuroda M, Nagasaki S, Ito R & Ohta T (2007) Sesquiterpene farnesol as a
1012 competitive inhibitor of lipase activity of *Staphylococcus aureus*. *FEMS*
1013 *Microbiol Lett* **273**: 28-34.
- 1014 Laroumagne S, Salinas-Pineda A, Hermant C, Murriss M, Gourraud PA, Do C,
1015 Segonds C, Didier A & Mazieres J (2011) Incidence and characteristics of
1016 bronchial colonisation in patient with lung cancer: a retrospective study of 388
1017 cases. *Revue des Maladies Respiratoires* **28**: 328-335.

- 1018 Laroumagne S, Lepage B, Hermant C, *et al.* (2013) Bronchial colonisation in
1019 patients with lung cancer: a prospective study. *The European Respiratory*
1020 *Journal* **42**: 220-229.
- 1021 Li L, Redding S & Dongari-Bagtzoglou A (2007) *Candida glabrata*: an
1022 emerging oral opportunistic pathogen. *Journal of Dental Research* **86**: 204-
1023 215.
- 1024 Lin YJ, Alsad L, Vogel F, Koppar S, Nevarez L, Auguste F, Seymour J, Syed
1025 A, Christoph K & Loomis JS (2013) Interactions between *Candida albicans*
1026 and *Staphylococcus aureus* within mixed species biofilms. *BIOS* **84**: 30-39.
- 1027 Loesche WJ (1986) Role of *Streptococcus mutans* in human dental decay.
1028 *Microbiol Rev* **50**: 353-380.
- 1029 Marcos-Arias C, Eraso E, Madariaga L, Aguirre JM & Quindos G (2011)
1030 Phospholipase and proteinase activities of *Candida* isolates from denture
1031 wearers. *Mycoses* **54**: e10-16.
- 1032 Martinez RC, Seney SL, Summers KL, Nomizo A, De Martinis EC & Reid G
1033 (2009) Effect of *Lactobacillus rhamnosus* GR-1 and *Lactobacillus reuteri* RC-
1034 14 on the ability of *Candida albicans* to infect cells and induce inflammation.
1035 *Microbiology and Immunology* **53**: 487-495.
- 1036 Mason KL, Erb Downward JR, Mason KD, Falkowski NR, Eaton KA, Kao JY,
1037 Young VB & Huffnagle GB (2012) *Candida albicans* and bacterial microbiota
1038 interactions in the cecum during recolonization following broad-spectrum
1039 antibiotic therapy. *Infection and Immunity* **80**: 3371-3380.
- 1040 McLean RJ (2014) Normal bacterial flora may inhibit *Candida albicans* biofilm
1041 formation by Autoinducer-2. *Frontiers in Cellular and Infection Microbiology* **4**:
1042 117.
- 1043 McNab R, Ford SK, El-Sabaeny A, Barbieri B, Cook GS & Lamont RJ (2003)
1044 LuxS-based signaling in *Streptococcus gordonii*: autoinducer 2 controls
1045 carbohydrate metabolism and biofilm formation with *Porphyromonas gingivalis*.
1046 *Journal of Bacteriology* **185**: 274-284.
- 1047 Mear JB, Gosset P, Kipnis E, *et al.* (2014) *Candida albicans* airway exposure
1048 primes the lung innate immune response against *Pseudomonas aeruginosa*
1049 infection through innate lymphoid cell recruitment and interleukin-22-
1050 associated mucosal response. *Infection and Immunity* **82**: 306-315.
- 1051 Mendonca FH, Santos SS, Faria Ida S, Goncalves e Silva CR, Jorge AO &
1052 Leao MV (2012) Effects of probiotic bacteria on *Candida* presence and IgA
1053 anti-*Candida* in the oral cavity of elderly. *Brazilian Dental Journal* **23**: 534-538.
- 1054 Metwalli KH, Khan SA, Krom BP & Jabra-Rizk MA (2013) *Streptococcus*
1055 *mutans*, *Candida albicans*, and the human mouth: a sticky situation. *PLoS*
1056 *Pathogens* **9**: e1003616.

- 1057 Millsap KW, Bos R, van der Mei HC & Busscher HJ (2001) Adhesive
1058 interactions between voice prosthetic yeast and bacteria on silicone rubber in
1059 the absence and presence of saliva. *Antonie van Leeuwenhoek* **79**: 337-343.
- 1060 Moore WEC, Holdeman LV, Smibert RM, Good IJ, Burmeister JA, Palcanis
1061 KG & Ranney RR (1982) Bacteriology of experimental gingivitis in young-adult
1062 humans. *Infection and Immunity* **38**: 651-667.
- 1063 Morales DK, Jacobs NJ, Rajamani S, Krishnamurthy M, Cubillos-Ruiz JR &
1064 Hogan DA (2010) Antifungal mechanisms by which a novel *Pseudomonas*
1065 *aeruginosa* phenazine toxin kills *Candida albicans* in biofilms. *Molecular*
1066 *Microbiology* **78**: 1379-1392.
- 1067 Nair N, Biswas R, Gotz F & Biswas L (2014) Impact of *Staphylococcus aureus*
1068 on pathogenesis in polymicrobial infections. *Infection and Immunity* **82**: 2162-
1069 2169.
- 1070 Nair RG & Samaranayake LP (1996) The effect of oral commensal bacteria
1071 on candidal adhesion to human buccal epithelial cells in vitro. *Journal of*
1072 *Medical Microbiology* **45**: 179-185.
- 1073 Nair RG, Anil S & Samaranayake LP (2001) The effect of oral bacteria on
1074 *Candida albicans* germ-tube formation. *APMIS* **109**: 147-154.
- 1075 Nash EE, Peters BM, Palmer GE, Fidel PL & Noverr MC (2014)
1076 Morphogenesis is not required for *Candida albicans-Staphylococcus aureus*
1077 intra-abdominal infection-mediated dissemination and lethal sepsis. *Infection*
1078 *and Immunity* **82**: 3426-3435.
- 1079 Nasution O, Srinivasa K, Kim M, Kim YJ, Kim W, Jeong W & Choi W (2008)
1080 Hydrogen peroxide induces hyphal differentiation in *Candida albicans*.
1081 *Eukaryotic Cell* **7**: 2008-2011.
- 1082 Nett JE (2014) Future directions for anti-biofilm therapeutics targeting
1083 *Candida*. *Expert Review of Anti-Infective Therapy* **12**: 375-382.
- 1084 Nett JE, Marchillo K, Spiegel CA & Andes DR (2010) Development and
1085 validation of an in vivo *Candida albicans* biofilm denture model. *Infection and*
1086 *Immunity* **78**: 3650-3659.
- 1087 Neu TR, Verkerke GJ, Herrmann IF, Schutte HK, Van der Mei HC & Busscher
1088 HJ (1994) Microflora on explanted silicone rubber voice prostheses: taxonomy,
1089 hydrophobicity and electrophoretic mobility. *The Journal of Applied*
1090 *Bacteriology* **76**: 521-528.
- 1091 Nikawa H, Hamada T & Yamamoto T (1998) Denture plaque - past and recent
1092 concerns. *Journal of Dentistry* **26**: 299-304.
- 1093 Nobbs AH & Jenkinson HF (2015) Interkingdom networking within the oral
1094 microbiome. *Microbes and Infection*. E-pub ahead of press.

- 1095 Noverr MC & Huffnagle GB (2004) Regulation of *Candida albicans*
1096 morphogenesis by fatty acid metabolites. *Infection and Immunity* **72**: 6206-
1097 6210.
- 1098 Oksala E (1990) Factors predisposing to oral yeast infections. *Acta Odontol*
1099 *Scand* **48**: 71-74.
- 1100 Orsi CF, Sabia C, Ardizzoni A, Colombari B, Neglia RG, Peppoloni S, Morace
1101 G & Blasi E (2014) Inhibitory effects of different lactobacilli on *Candida*
1102 *albicans* hyphal formation and biofilm development. *Journal of Biological*
1103 *Regulators and Homeostatic Agents* **28**: 743-752.
- 1104 Pammi M, Liang R, Hicks J, Mistretta TA & Versalovic J (2013) Biofilm
1105 extracellular DNA enhances mixed species biofilms of *Staphylococcus*
1106 *epidermidis* and *Candida albicans*. *BMC Microbiology* **13**: 257.
- 1107 Peciuliene V, Reynaud AH, Balciuniene I & Haapasalo M (2001) Isolation of
1108 yeasts and enteric bacteria in root-filled teeth with chronic apical periodontitis.
1109 *International Endodontic Journal* **34**: 429-434.
- 1110 Perlroth J, Choi B & Spellberg B (2007) Nosocomial fungal infections:
1111 epidemiology, diagnosis, and treatment. *Medical Mycology* **45**: 321-346.
- 1112 Peters BM & Noverr MC (2013) *Candida albicans-Staphylococcus aureus*
1113 polymicrobial peritonitis modulates host innate immunity. *Infection and*
1114 *Immunity* **81**: 2178-2189.
- 1115 Peters BM, Jabra-Rizk MA, O'May GA, Costerton JW & Shirtliff ME (2012)
1116 Polymicrobial interactions: impact on pathogenesis and human disease.
1117 *Clinical Microbiology Reviews* **25**: 193-213.
- 1118 Peters BM, Ward RM, Rane HS, Lee SA & Noverr MC (2013) Efficacy of
1119 ethanol against *Candida albicans* and *Staphylococcus aureus* polymicrobial
1120 biofilms. *Antimicrobial Agents and Chemotherapy* **57**: 74-82.
- 1121 Peters BM, Jabra-Rizk MA, Scheper MA, Leid JG, Costerton JW & Shirtliff ME
1122 (2010) Microbial interactions and differential protein expression in
1123 *Staphylococcus aureus-Candida albicans* dual-species biofilms. *FEMS*
1124 *Immunology and Medical Microbiology* **59**: 493-503.
- 1125 Peters BM, Ovchinnikova ES, Krom BP, Schlecht LM, Zhou H, Hoyer LL,
1126 Busscher HJ, van der Mei HC, Jabra-Rizk MA & Shirtliff ME (2012)
1127 *Staphylococcus aureus* adherence to *Candida albicans* hyphae is mediated
1128 by the hyphal adhesin Als3p. *Microbiology* **158**: 2975-2986.
- 1129 Przybyłowska D, Rubinsztajn R, Chazan R, Swoboda-Kopec E, Kostrzewa-
1130 Janicka J & Mierzwińska-Nastalska E (2015) The prevalence of oral
1131 inflammation among denture wearing patients with chronic obstructive
1132 pulmonary disease. *Advances in Experimental Medicine and Biology*. E-pub
1133 ahead of print.

- 1134 Rajendran R, Sherry L, Lappin DF, Nile CJ, Smith K, Williams C, Munro CA &
1135 Ramage G (2014) Extracellular DNA release confers heterogeneity in
1136 *Candida albicans* biofilm formation. *BMC Microbiology* **14**: 303.
- 1137 Ramage G, Robertson SN & Williams C (2014) Strength in numbers:
1138 antifungal strategies against fungal biofilms. *International Journal of*
1139 *Antimicrobial Agents* **43**: 114-120.
- 1140 Ramage G, Saville SP, Wickes BL & Lopez-Ribot JL (2002) Inhibition of
1141 *Candida albicans* biofilm formation by farnesol, a quorum-sensing molecule.
1142 *Appl Environ Microb* **68**: 5459-5463.
- 1143 Ramage G, VandeWalle K, Lopez-Ribot JL & Wickes BL (2002) The
1144 filamentation pathway controlled by the Efg1 regulator protein is required for
1145 normal biofilm formation and development in *Candida albicans*. *FEMS*
1146 *Microbiol Lett* **214**: 95-100.
- 1147 Ramage G, Tomsett K, Wickes BL, Lopez-Ribot JL & Redding SW (2004)
1148 Denture stomatitis: A role for *Candida* biofilms. *Oral Surg Oral Med O* **98**: 53-
1149 59.
- 1150 Ramage G, Tomsett K, Wickes BL, Lopez-Ribot JL & Redding SW (2004)
1151 Denture stomatitis: a role for *Candida* biofilms. *Oral Surg Oral Med Oral*
1152 *Pathol Oral Radiol Endod* **98**: 53-59.
- 1153 Ramage G, Zalewska A, Cameron DA, Sherry L, Murray C, Finnegan MB,
1154 Loewy ZG & Jagger DC (2012) A comparative in vitro study of two denture
1155 cleaning techniques as an effective strategy for inhibiting *Candida albicans*
1156 biofilms on denture surfaces and reducing inflammation. *Journal of*
1157 *Prosthodontics* **21**: 516-522.
- 1158 Rams TE, Babalola OO & Slots J (1990) Subgingival occurrence of enteric
1159 rods, yeasts and staphylococci after systemic doxycycline therapy. *Oral*
1160 *Microbiology and Immunology* **5**: 166-168.
- 1161 Rautemaa R & Ramage G (2011) Oral candidosis--clinical challenges of a
1162 biofilm disease. *Crit Rev Microbiol* **37**: 328-336.
- 1163 Redding SW, Marr KA, Kirkpatrick WR, Coco BJ & Patterson TF (2004)
1164 *Candida glabrata* sepsis secondary to oral colonization in bone marrow
1165 transplantation. *Medical Mycology* **42**: 479-481.
- 1166 Ribeiro DG, Pavarina AC, Dovigo LN, Machado AL, Giampaolo ET & Vergani
1167 CE (2012) Prevalence of *Candida* spp. associated with bacteria species on
1168 complete dentures. *Gerodontology* **29**: 203-208.
- 1169 Romani L, Zelante T, Palmieri M, Napolioni V, Picciolini M, Velardi A, Aversa
1170 F & Puccetti P (2015) The cross-talk between opportunistic fungi and the
1171 mammalian host via microbiota's metabolism. *Seminars in Immunopathology*
1172 **37**: 163-171.

- 1173 Roux D, Gaudry S, Dreyfuss D, El-Benna J, de Prost N, Denamur E, Saumon
 1174 G & Ricard JD (2009) *Candida albicans* impairs macrophage function and
 1175 facilitates *Pseudomonas aeruginosa* pneumonia in rat. *Critical Care Medicine*
 1176 **37**: 1062-1067.
- 1177 Sachdeo A, Haffajee AD & Socransky SS (2008) Biofilms in the edentulous
 1178 oral cavity. *Journal of Prosthodontics* **17**: 348-356.
- 1179 Salerno C, Pascale M, Contaldo M, Esposito V, Busciolano M, Milillo L, Guida
 1180 A, Petruzzi M & Serpico R (2011) *Candida*-associated denture stomatitis.
 1181 *Medicina Oral, Patologia Oral y Cirugia Bucal* **16**: e139-143.
- 1182 Sapaar B, Nur A, Hirota K, Yumoto H, Murakami K, Amoh T, Matsuo T,
 1183 Ichikawa T & Miyake Y (2014) Effects of extracellular DNA from *Candida*
 1184 *albicans* and pneumonia-related pathogens on *Candida* biofilm formation and
 1185 hyphal transformation. *Journal of Applied Microbiology* **116**: 1531-1542.
- 1186 Sardi JC, Duque C, Mariano FS, Peixoto IT, Hofling JF & Goncalves RB
 1187 (2010) *Candida* spp. in periodontal disease: a brief review. *J Oral Sci* **52**: 177-
 1188 185.
- 1189 Sardi JC, Duque C, Mariano FS, Marques MR, Hofling JF & Goncalves RB
 1190 (2012) Adhesion and invasion of *Candida albicans* from periodontal pockets
 1191 of patients with chronic periodontitis and diabetes to gingival human
 1192 fibroblasts. *Medical Mycology* **50**: 43-49.
- 1193 Schlecht LM, Peters BM, Krom BP, Freiberg JA, Hansch GM, Filler SG,
 1194 Jabra-Rizk MA & Shirtliff ME (2015) Systemic *Staphylococcus aureus*
 1195 infection mediated by *Candida albicans* hyphal invasion of mucosal tissue.
 1196 *Microbiology* **161**: 168-181.
- 1197 Sen BH, Safavi KE & Spangberg LS (1997) Growth patterns of *Candida*
 1198 *albicans* in relation to radicular dentin. *Oral Surgery, Oral Medicine, Oral*
 1199 *Pathology, Oral Radiology, and Endodontics* **84**: 68-73.
- 1200 Shi B, Chang M, Martin J, Mitreva M, Lux R, Klokkevold P, Sodergren E,
 1201 Weinstock GM, Haake SK & Li H (2015) Dynamic changes in the subgingival
 1202 microbiome and their potential for diagnosis and prognosis of periodontitis.
 1203 *mBio* **6**: e01926-01914.
- 1204 Shirtliff ME, Peters BM & Jabra-Rizk MA (2009) Cross-kingdom interactions:
 1205 *Candida albicans* and bacteria. *FEMS Microbiol Lett* **299**: 1-8.
- 1206 Silva S, Henriques M, Hayes A, Oliveira R, Azeredo J & Williams DW (2011)
 1207 *Candida glabrata* and *Candida albicans* co-infection of an in vitro oral
 1208 epithelium. *J Oral Pathol Med* **40**: 421-427.
- 1209 Simon-Soro A, Guillen-Navarro M & Mira A (2014) Metatranscriptomics
 1210 reveals overall active bacterial composition in caries lesions. *J Oral Microbiol*
 1211 **6**: 25443.

- 1212 Siqueira JF, Jr. & Sen BH (2004) Fungi in endodontic infections. *Oral Surgery,*
1213 *Oral Medicine, Oral Pathology, Oral Radiology, and Endodontics* **97**: 632-641.
- 1214 Siqueira JF, Jr. & Rocas IN (2009) Diversity of endodontic microbiota revisited.
1215 *Journal of Dental Research* **88**: 969-981.
- 1216 Socransky SS & Haffajee AD (2005) Periodontal microbial ecology.
1217 *Periodontology 2000* **38**: 135-187.
- 1218 Socransky SS, Haffajee AD, Cugini MA, Smith C & Kent RL, Jr. (1998)
1219 Microbial complexes in subgingival plaque. *Journal of Clinical Periodontology*
1220 **25**: 134-144.
- 1221 Soysa NS & Ellepola AN (2005) The impact of cigarette/tobacco smoking on
1222 oral candidosis: an overview. *Oral Dis* **11**: 268-273.
- 1223 Soysa NS, Samaranayake LP & Ellepola AN (2004) Cytotoxic drugs,
1224 radiotherapy and oral candidiasis. *Oral Oncol* **40**: 971-978.
- 1225 Soysa NS, Samaranayake LP & Ellepola AN (2006) Diabetes mellitus as a
1226 contributory factor in oral candidosis. *Diabet Med* **23**: 455-459.
- 1227 Spinillo A, Capuzzo E, Nicola S, Baltaro F, Ferrari A & Monaco A (1995) The
1228 impact of oral contraception on vulvovaginal candidiasis. *Contraception* **51**:
1229 **293-297**.
- 1230 Stacy A, Everett J, Jorth P, Trivedi U, Rumbaugh KP & Whiteley M (2014)
1231 Bacterial fight-and-flight responses enhance virulence in a polymicrobial
1232 infection. *Proceedings of the National Academy of Sciences of the United*
1233 *States of America* **111**: 7819-7824.
- 1234 Strus M, Kucharska A, Kukla G, Brzychczy-Wloch M, Maresz K & Heczko PB
1235 (2005) The in vitro activity of vaginal *Lactobacillus* with probiotic properties
1236 against *Candida*. *Infectious Diseases in Obstetrics and Gynecology* **13**: 69-75.
- 1237 Sud IJ & Feingold DS (1982) Action of antifungal imidazoles on
1238 *Staphylococcus aureus*. *Antimicrobial Agents and Chemotherapy* **22**: 470-474.
- 1239 Swidergall M, Ernst AM & Ernst JF (2013) *Candida albicans* mucin Msb2 is a
1240 broad-range protectant against antimicrobial peptides. *Antimicrobial Agents*
1241 *and Chemotherapy* **57**: 3917-3922.
- 1242 Syed SA & Loesche WJ (1978) Bacteriology of human experimental gingivitis:
1243 effect of plaque age. *Infection and Immunity* **21**: 821-829.
- 1244 Taff HT, Nett JE, Zarnowski R, Ross KM, Sanchez H, Cain MT, Hamaker J,
1245 Mitchell AP & Andes DR (2012) A *Candida* biofilm-induced pathway for matrix
1246 glucan delivery: implications for drug resistance. *PLoS Pathogens* **8**:
1247 e1002848.
- 1248 Takahashi N & Nyvad B (2011) The role of bacteria in the caries process:
1249 ecological perspectives. *Journal of Dental Research* **90**: 294-303.

- 1250 Talpaert MJ, Balfour A, Stevens S, Baker M, Muhlschlegel FA & Gourlay CW
 1251 (2015) *Candida* biofilm formation on voice prostheses. *Journal of Medical*
 1252 *Microbiology* **64**: 199-208.
- 1253 Tamai R, Sugamata M & Kiyoura Y (2011) *Candida albicans* enhances
 1254 invasion of human gingival epithelial cells and gingival fibroblasts by
 1255 *Porphyromonas gingivalis*. *Microbial Pathogenesis* **51**: 250-254.
- 1256 Tawara Y, Honma K & Naito Y (1996) Methicillin-resistant *Staphylococcus*
 1257 *aureus* and *Candida albicans* on denture surfaces. *The Bulletin of Tokyo*
 1258 *Dental College* **37**: 119-128.
- 1259 Teles FR, Teles RP, Sachdeo A, Uzel NG, Song XQ, Torresyap G, Singh M,
 1260 Papas A, Haffajee AD & Socransky SS (2012) Comparison of microbial
 1261 changes in early redeveloping biofilms on natural teeth and dentures. *Journal*
 1262 *of Periodontology* **83**: 1139-1148.
- 1263 Thein ZM, Samaranayake YH & Samaranayake LP (2006) Effect of oral
 1264 bacteria on growth and survival of *Candida albicans* biofilms. *Archives of Oral*
 1265 *Biology* **51**: 672-680.
- 1266 Unnanuntana A, Bonsignore L, Shirtliff ME & Greenfield EM (2009) The
 1267 effects of farnesol on *Staphylococcus aureus* biofilms and osteoblasts. An in
 1268 vitro study. *The Journal of Bone and Joint Surgery* **91**: 2683-2692.
- 1269 Vadiraj S, Nayak R, Choudhary GK, Kudyar N & Spoorthi BR (2013)
 1270 Periodontal pathogens and respiratory diseases-evaluating their potential
 1271 association: a clinical and microbiological study. *The Journal of Contemporary*
 1272 *Dental pPractice* **14**: 610-615.
- 1273 van Weissenbruch R, Bouckaert S, Remon JP, Nelis HJ, Aerts R & Albers FW
 1274 (1997a) Chemoprophylaxis of fungal deterioration of the Provox silicone
 1275 tracheoesophageal prosthesis in postlaryngectomy patients. *The Annals of*
 1276 *Otology, Rhinology, and Laryngology* **106**: 329-337.
- 1277 van Weissenbruch R, Albers FW, Bouckaert S, Nelis HJ, Criel G, Remon JP &
 1278 Sulter AM (1997b) Deterioration of the Provox silicone tracheoesophageal
 1279 voice prosthesis: microbial aspects and structural changes. *Acta Oto-*
 1280 *laryngologica* **117**: 452-458.
- 1281 Vendeville A, Winzer K, Heurlier K, Tang CM & Hardie KR (2005) Making
 1282 'sense' of metabolism: autoinducer-2, LuxS and pathogenic bacteria. *Nat Rev*
 1283 *Microbiol* **3**: 383-396.
- 1284 Verran J, Jackson S, Coulthwaite L, Scallan A, Loewy Z & Whitehead K
 1285 (2014) The effect of dentifrice abrasion on denture topography and the
 1286 subsequent retention of microorganisms on abraded surfaces. *The Journal of*
 1287 *Prosthetic Dentistry* **112**: 1513-1522.
- 1288 Vos T & Flaxman AD & Naghavi M, *et al.* (2012) Years lived with disability
 1289 (YLDs) for 1160 sequelae of 289 diseases and injuries 1990-2010: a

- 1290 systematic analysis for the global burden of disease study 2010. *Lancet* **380**:
1291 2163-2196.
- 1292 Williams DW, Kuriyama T, Silva S, Malic S & Lewis MA (2011) *Candida*
1293 biofilms and oral candidosis: treatment and prevention. *Periodontology 2000*
1294 **55**: 250-265.
- 1295 Ximenez-Fyvie LA, Haffajee AD & Socransky SS (2000) Comparison of the
1296 microbiota of supra- and subgingival plaque in health and periodontitis.
1297 *Journal of Clinical Periodontology* **27**: 648-657.
- 1298 Xu H, Sobue T, Thompson A, Xie Z, Poon K, Ricker A, Cervantes J, Diaz PI &
1299 Dongari-Bagtzoglou A (2014) Streptococcal co-infection augments *Candida*
1300 pathogenicity by amplifying the mucosal inflammatory response. *Cellular*
1301 *Microbiology* **16**: 214-231.
- 1302 Yasui M, Ryu M, Sakurai K & Ishihara K (2012) Colonisation of the oral cavity
1303 by periodontopathic bacteria in complete denture wearers. *Gerodontology* **29**:
1304 e494-502.
- 1305 Yi Jey Lin LA, Fabio Vogel, Shardul Koppar, Leslie Nevarez, Fabrice Auguste,
1306 John Seymour, Aisha Syed, Kristina Christoph, and Joshua S. Loomis (2013)
1307 Interactions between *Candida albicans* and *Staphylococcus aureus* within
1308 mixed species biofilms. *BioOne* **84**: 30-39.
- 1309 Young G, Krasner RI & Yudkofsky PL (1956) Interactions of oral strains of
1310 *Candida albicans* and lactobacilli. *Journal of Bacteriology* **72**: 525-529.
- 1311 Zakout YM, Salih MM & Ahmed HG (2012) Frequency of *Candida* species in
1312 papanicolaou smears taken from Sudanese oral hormonal contraceptives
1313 users. *Biotechnic & Histochemistry* **87**: 95-97.
- 1314
- 1315
- 1316
- 1317
- 1318
- 1319
- 1320
- 1321
- 1322
- 1323
- 1324
- 1325
- 1326

1327

1328

1329

1330 **Figure legends**

1331

1332 **Figure 1: Interactions between *Candida albicans* and bacteria.**

1333 *Candida albicans* coaggregating with either (A) Gram-negative and (B) Gram-
1334 positive bacteria, or (C) a polymicrobial biofilm aggregate consisting of Gram-
1335 positive and Gram-negative oral bacterial species interacting with *C. albicans*
1336 hyphae. White scale bars = 20um. Confocal Image taken by Dr Owain
1337 Millington, Biophotonics Unit, Strathclyde University)

1338

1339 **Figure 2: Oral sites of polymicrobial *Candida* biofilm diseases.**

1340 The schematic diagram illustrates site within the oral cavity typically where
1341 *Candida*-bacterial polymicrobial biofilms are observed (clockwise from top
1342 position): caries, periodontitis, orthodontic, endodontic, angular cheilitis,
1343 denture stomatitis.

1344

1345 **Figure 3: Micrographs of polymicrobial *Candida* denture related**

1346 **biofilms.** (A) Scanning electron micrograph (SEM) and (B) confocal laser
1347 scanning micrograph (CLSM) of complex bacterial communities
1348 coaggregating with *Candida albicans* upon denture acrylic. These
1349 micrographs show low (SEM) and high (CLSM) magnifications of mixtures of
1350 *C. albicans* yeast (round) and hyphae (long filaments – white arrows)
1351 coaggregated with smaller bacterial species. Confocal Image taken by Dr
1352 Owain Millington, Biophotonics Unit, Strathclyde University).

1353

1354 **Figure 4: Development of polymicrobial *Candida* biofilm on denture**

1355 **acrylic.** This schematic representation of denture biofilm development shows
1356 how initial colonisation by yeast and bacterial species (white), followed by
1357 hyphal formation and co-aggregation (grey), which then enables the bacterial
1358 species to expand and grow into the spaces unoccupied on the surface of
1359 both the acrylic and *C. albicans* hyphae (black).

1360

1361 **Figure 5: *Candida albicans* and *Staphylococcus aureus* polymicrobial**
1362 **biofilm.** This confocal scanning laser micrograph shows the close interactions
1363 between clusters of *S. aureus* (yellow) and *C. albicans* hyphae (white/green).
1364 The appearance of these interactions demonstrates close attachment
1365 between the two in three-dimensional space, suggesting structural stability
1366 and an element of co-operation with one-another. Confocal Image taken by Dr
1367 Owain Millington, Biophotonics Unit, Strathclyde University)